摘要：Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53.

参考文献：

[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53.

[2] 中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会, 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2020版）[J]. 中华肿瘤杂志, 2020, 42(12):1063-1077.

[3] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.

[4] Editorial Office of Chinese Journal of Lung Cancer. Zhongguo Fei Ai Za Zhi. 2023;26(6):416-428.

[5] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.

[6] 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2024版.

[7] 中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌MET临床检测中国专家共识 [J] . 中华病理学杂志, 2022, 51(11) : 1094-1103.

[8] 中国老年保健协会肺癌专业委员会.MET 14外显子跳跃突变NSCLC靶向治疗专家共识.中国肺癌杂志,2023,26(6):416-428.

[9] Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018;123:76-82.

[10] Huang C, Zou Q, Liu H, et al. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. Curr Treat Options Oncol. 2020;21(4):33.

[11] Wolf Jürgen, Hochmair Maximilian, Han Ji-Youn, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol, 2024, 25: 1357-1370.

[12] Yi-Long Wu, et al. Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study. 2022 ESMO AISA, 388P.

[13] Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015;17(1):122-128.

[14] Schoenmaekers JJAO, Paats MS, Dingemans AC, Hendriks LEL. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. Transl Lung Cancer Res. 2020;9(6):2599-2617.

[15] Fujino T, et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol. 2019 Oct;14(10):1753-1765.

[16] Paik PK, et al. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-228.

[17]《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》http://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=de66e92b7edd4056ac41c0c4d3c011f3.pdf .

[18] 张力, 王永生, 林丽珠, 等. 赛沃替尼相关不良反应管理的中国多学科专家共识[J]. 中华肿瘤杂志, 2023, 45(4):298-312.

[19] 简明处方：https://www.medlive.cn/recommond.php?kyprojectid=1_002094401_1&hash=DaGO1J

撰写：Coco

审校：Coco

排版：Yian

执行：Uni

来源：医脉通肿瘤科